Cardiovascular Therapeutics

Research Article

Comparison between High-Power Short-Duration and Conventional Ablation Strategy in Atrial Fibrillation: An Updated Meta-Analysis

Table 1

Characteristics of included studies.

(a)


Study ID (author, year)	Country	Treatment group	Patients ()	Male (, %)	Age (Y)	Paroxysmal AF (, %)	CHA₂DS₂-VASCs	LAD (mm) or size	Follow-up period (month)	Study design	NOS

Nilsson, 2006 [7]	Denmark	HPSD	45	15 (33)		26 (58)	N/A	N/A	(range 5–25 months)	Retrospective	8
Nilsson, 2006 [7]	Denmark	LPLD	45	36 (80)		21 (47)	N/A	N/A	(range 5–25 months)	Retrospective	8
Yamada, 2006 [20]	Japan	HPSD	61	51 (84)		61 (100)	N/A		6	Retrospective	8
Yamada, 2006 [20]	Japan	LPLD	47	40 (85)		47 (100)	N/A		6	Retrospective	8
Dhillon, 2019 [35]	United Kingdom	HPAI	50	35 (70)	N/A	50 (100)	N/A	N/A	12	Prospective	7
Dhillon, 2019 [35]	United Kingdom	Conventional	50	24 (48)	N/A	50 (100)	N/A	N/A	12	Prospective	7
Berte, 2019 [37]	Switzerland	HPSD-CLOSE	80	50 (63)		65 (81)	N/A	N/A	6	Prospective	8
Berte, 2019 [37]	Switzerland	Standard-CLOSE	94	67 (71)		74 (79)	N/A	N/A	6	Prospective	8
Okamatsu, 2019 [27]	Japan	HP	20	13 (65)		13 (65)	2 (1-3)		6.5 (6.3-6.7)	Prospective observational	7
Okamatsu, 2019 [27]	Japan	LP	20	15 (75)		16 (80)	2 (1-2)		6.5 (6.3-6.7)	Prospective observational	7
Pambrun, 2019 [25]	French	HPSD	50	35 (70)		50 (100)	N/A	mL^a	12	Prospective	9
Pambrun, 2019 [25]	French	LPLD	50	30 (60)		50 (100)	N/A	mL^a	12	Prospective	9
Vassallo, 2019 [22]	Brazel	HPSD	41	34 (83)		28 (68)		43.3 (28-62)	12	Retrospective	9
Vassallo, 2019 [22]	Brazel	Conventional	35	22 (63)		27 (77)		41.9 (23-56)	12	Retrospective	9
Castrejón-Castrejón, 2020 [36]	Spain	HPSD	48	32 (67)		31 (65)	N/A	N/A	3	Retrospective	6
Castrejón-Castrejón, 2020 [36]	Spain	Conventional	47	28 (60)		30 (64)	N/A	N/A	3	Retrospective	6
Ejima, 2020 [33]	Japan	HPSD	60	44 (73)		60 (100)				Prospective cohort	8
Ejima, 2020 [33]	Japan	Conventional	60	42 (70)		60 (100)				Prospective cohort	8
Kottmaier, 2020 [8]	Germany	VHPSD	97	57 (59)		97 (100)	1.95	N/A	12	Prospective	9
Kottmaier, 2020 [8]	Germany	LPLD	100	60 (60)		100 (100)	1.64	N/A	12	Prospective	9
Kyriakopoulou, 2020 [30]	Belgium	HPSD	80	47 (59)	67 (58-73)	80 (100)	2 (1-3)		12	Retrospective	8
Kyriakopoulou, 2020 [30]	Belgium	LPLD	105	65 (62)	64 (56-69)	105 (100)	2 (1-2)		12	Retrospective	8
Leo, 2020 [28]	United Kingdom	HPSD	40	26 (65)		16 (40)	N/A			Prospective, randomized, unblinded	8
Leo, 2020 [28]	United Kingdom	LPLD	40	33 (83)		15 (38)	N/A			Prospective, randomized, unblinded	8
Shin, 2020 [23]	Korea	HPSD	100	81 (81)		48 (48)			12	Prospective randomized controlled trial	7
Shin, 2020 [23]	Korea	LPLD	50	33 (66)		24 (48)			12	Prospective randomized controlled trial	7
Yavin, 2020 [19]	USA	HPSD	112	71 (63)		76 (68)			14.2 (1.9-35)	Prospective	7
Yavin, 2020 [19]	USA	MPLD	112	79 (71)		67 (60)			22.8 (3-43.9)	Prospective	7
Yazaki, 2020 [18]	Japan	HPSD	32	27 (84)		22 (69)	N/A		10 (4–12)	Retrospective	7
Yazaki, 2020 [18]	Japan	LPLD	32	20 (63)		29 (91)	N/A		10 (4–12)	Retrospective	7
Dikdan, 2021 [34]	USA	HPSD	76	54 (71)		32 (42)	2 (1-3)	mL^a	12	Retrospective	9
Dikdan, 2021 [34]	USA	SPSD	51	40 (78)		21 (41)	1 (1-2)	mL^a	12	Retrospective	9
Wielandts, 2021 [21]	Belgium	HP-CLOSE	48	32 (67)		48 (100)	1 (0-3)		6	Prospective randomized controlled	8
Wielandts, 2021 [21]	Belgium	LP-CLOSE	48	33 (69)		48 (100)	1 (0-3)		6	Prospective randomized controlled	8

(b)


Study ID (author, year)	Country	Treatment group	Patients ()	Male (, %)	Age (Y)	Paroxysmal AF (, %)	CHA₂DS₂-VASCs	LAD (mm) or size	Follow-up period (month)	Type of study	NOS

Francke, 2021 [32]	Germany	HP-CLOSE	100	60 (60)		49 (49)		N/A		Prospective trial	8
Francke, 2021 [32]	Germany	Standard-CLOSE	20	7 (35)		9 (45)		N/A	3	Prospective trial	8
Hansom, 2021 [31]	Canada	HPSD	107	69 (64)		67 (63)	1.9		12	Retrospective cohort	8
Hansom, 2021 [31]	Canada	FTI-guided LDLD	107	81 (76)		60 (56)	2		12	Retrospective cohort	8
Richard, 2021 [24]	Germany	VHPSD	28	21 (75)	69 (61-73)	11 (39)	N/A	26 (25-35)^b	N/A	Prospective	7
Richard, 2021 [24]	Germany	Conventional	28	19 (68)	69 (62-75)	14 (50)	N/A	32 (26-39)^b	N/A	Prospective	7
Lee, 2021	Korea	HPAI	86	66 (77)		62 (72)	1 (1-2)		12	Prospective	8
Lee, 2021	Korea	CPAI	32	25 (78)		24 (75)	1 (0-2)		12	Prospective	8
Okamatsu, 2021 [26]	Japan	HP	1032	716 (69)	68 (61-74)	583 (56)	2 (1-3)	41 (37-46)	12	Retrospective	8
Okamatsu, 2021 [26]	Japan	CP	301	210 (70)	67 (61-73)	172 (57)	2 (1-3)	41 (37-46)	12	Retrospective	8

Values are presented as , medians (interquartile range), or (%). ^aThe left atrium size was measured by left atrial volume in mL; ^bthe left atrial size was presented with the unit of ml/m² per body surface area. BMI: body mass index; CHA2DS2-VASCs: 1 point for each of congestive heart failure, hypertension, diabetes, vascular disease, age of 65-74 years old or female, 2 points for each of stroke or years old; LAD: left atrium diameter; LVEF: left ventricular eject fraction; HPSD: high-power short-duration; LPLD: low-power long-duration; HPAI: high-power ablation index- (AI-) guided; CLOSE: CLOSE protocol; HP: high-power; LP: low-power; VHPSD: very-high-power short-duration; MPLD: moderate-power moderate-duration; CPAI: conventional-power AI-guided.